Literature DB >> 10851075

The Rgr oncogene (homologous to RalGDS) induces transformation and gene expression by activating Ras, Ral and Rho mediated pathways.

I Hernandez-Muñoz1, M Malumbres, P Leonardi, A Pellicer.   

Abstract

The effects of the 5'-truncated Rgr oncogene, a previously shown specific guanine exchange factor for Ral in vitro, in stimulating proliferation, cell transformation and gene expression were investigated. We have established TetRgr cell lines in which expression of Rgr can be inhibited by the presence of tetracycline in the medium. Using this system, we show that Rgr overexpressing cells are morphologically transformed and grow in a disorganized manner. At the transcriptional level, Rgr enhances the activity of the serum response element and c-Jun. Rgr induces phosphorylation of ERKs, p38 and JNK kinases, and increases the levels of the GTP-bound forms of Ral and Ras. Ras activation could account for the broad spectra of effects displayed by Rgr. The important role of these pathways is confirmed by experiments in which the transcriptional activation events can be blocked by dominant negative versions of Ras, Ral and Rho. Among all the Rgr-induced pathways, the Ras-Raf-MEK-ERK cascade is essential for the transforming properties of Rgr. Additional analysis has shown that the activation of this pathway by Rgr is not due to a feed back mechanism mediated by the Grb2 adaptor protein. Oncogene (2000).

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10851075     DOI: 10.1038/sj.onc.1203586

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  11 in total

Review 1.  C3 exoenzymes, novel insights into structure and action of Rho-ADP-ribosylating toxins.

Authors:  Martin Vogelsgesang; Alexander Pautsch; Klaus Aktories
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2006-12-05       Impact factor: 3.000

2.  Negative regulation of the RalGAP complex by 14-3-3.

Authors:  Dara Leto; Maeran Uhm; Anja Williams; Xiao-wei Chen; Alan R Saltiel
Journal:  J Biol Chem       Date:  2013-02-05       Impact factor: 5.157

3.  Crystal structure of the C3bot-RalA complex reveals a novel type of action of a bacterial exoenzyme.

Authors:  Alexander Pautsch; Martin Vogelsgesang; Jens Tränkle; Christian Herrmann; Klaus Aktories
Journal:  EMBO J       Date:  2005-09-22       Impact factor: 11.598

4.  p15(INK4b) plays a crucial role in murine lymphoid development and tumorigenesis.

Authors:  Kwame Osei-Sarfo; Ignacio Perez de Castro; Angel Pellicer
Journal:  Carcinogenesis       Date:  2012-01-06       Impact factor: 4.944

5.  The RalGEF-Ral Effector Signaling Network: The Road Less Traveled for Anti-Ras Drug Discovery.

Authors:  Nicole F Neel; Timothy D Martin; Jeran K Stratford; Tanya P Zand; David J Reiner; Channing J Der
Journal:  Genes Cancer       Date:  2011-03

6.  Cyclic AMP-mediated inhibition of cell growth requires the small G protein Rap1.

Authors:  J M Schmitt; P J Stork
Journal:  Mol Cell Biol       Date:  2001-06       Impact factor: 4.272

7.  The human Rgr oncogene is overexpressed in T-cell malignancies and induces transformation by acting as a GEF for Ras and Ral.

Authors:  K Osei-Sarfo; L Martello; S Ibrahim; A Pellicer
Journal:  Oncogene       Date:  2011-03-28       Impact factor: 9.867

8.  Development of a Bioinformatics Framework for Identification and Validation of Genomic Biomarkers and Key Immunopathology Processes and Controllers in Infectious and Non-infectious Severe Inflammatory Response Syndrome.

Authors:  Dong Ling Tong; Karen E Kempsell; Tamas Szakmany; Graham Ball
Journal:  Front Immunol       Date:  2020-03-31       Impact factor: 7.561

9.  Demographic and genetic factors influence the abundance of infiltrating immune cells in human tissues.

Authors:  Andrew G Clark; Olivier Elemento; Andrew R Marderstein; Manik Uppal; Akanksha Verma; Bhavneet Bhinder; Zakieh Tayyebi; Jason Mezey
Journal:  Nat Commun       Date:  2020-05-05       Impact factor: 14.919

10.  Genomic markers of midostaurin drug sensitivity in FLT3 mutated and FLT3 wild-type acute myeloid leukemia patients.

Authors:  Mara W Rosenberg; Kevin Watanabe-Smith; Jeffrey W Tyner; Cristina E Tognon; Brian J Druker; Uma Borate
Journal:  Oncotarget       Date:  2020-07-21
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.